Loading clinical trials...
Loading clinical trials...
A Multi-part, Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability and Efficacy of Tropifexor (LJN452) in Patients With Primary Biliary Cholangitis
Conditions
Interventions
Part 1: LJN452
Part 1: Placebo
+3 more
Locations
28
United States
Novartis Investigative Site
Rialto, California, United States
Novartis Investigative Site
Miami, Florida, United States
Novartis Investigative Site
Atlanta, Georgia, United States
Novartis Investigative Site
Marietta, Georgia, United States
Novartis Investigative Site
Chicago, Illinois, United States
Novartis Investigative Site
Manhasset, New York, United States
Start Date
September 9, 2015
Primary Completion Date
August 2, 2018
Completion Date
August 2, 2018
Last Updated
January 5, 2021
NCT07304843
NCT07449793
NCT06755541
NCT05749822
NCT05751967
NCT07296458
Lead Sponsor
Novartis Pharmaceuticals
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions